Amylyx Pharmaceuticals (AMLX) Gross Profit (2022 - 2024)
Historic Gross Profit for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Q4 2024 value amounting to $26.2 million.
- Amylyx Pharmaceuticals' Gross Profit fell 7763.0% to $26.2 million in Q4 2024 from the same period last year, while for Sep 2025 it was $26.2 million, marking a year-over-year decrease of 8697.54%. This contributed to the annual value of $108.3 million for FY2024, which is 7332.16% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Gross Profit of $26.2 million as of Q4 2024, which was down 7763.0% from $416000.0 recorded in Q3 2024.
- In the past 5 years, Amylyx Pharmaceuticals' Gross Profit registered a high of $117.3 million during Q4 2023, and its lowest value of $375000.0 during Q3 2022.
- Moreover, its 3-year median value for Gross Profit was $52.7 million (2023), whereas its average is $54.0 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Gross Profit soared by 2833893.33% in 2023 and then tumbled by 9960.99% in 2024.
- Over the past 3 years, Amylyx Pharmaceuticals' Gross Profit (Quarter) stood at $23.7 million in 2022, then skyrocketed by 393.98% to $117.3 million in 2023, then plummeted by 77.63% to $26.2 million in 2024.
- Its last three reported values are $26.2 million in Q4 2024, $416000.0 for Q3 2024, and $1.0 million during Q2 2024.